The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
The BioCentury Show
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-precarious biotech financing landscape.
View full story: https://www.biocentury.com/article/653858
#biotech #biopharma #pharma #lifescience #IPO #capitalmarkets #deals
00:00 - Introduction
02:17 - Capital Markets Outlook
05:18 - M&A
14:37 - Breaking Down Deals
23:44 - Asia